This is a non-core endpoint: only basic statistics are computed.
Use of fingolimod
MSMED_FINGOLIMOD
No definition available.
Endpoint definition
↥392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
1 out of 7 registries used, show all original rules.
253
Check minimum number of events
253
Include endpoints None
253
Remove individuals based on genotype QC
236
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to Use of fingolimod based on the number of shared cases.
Broader endpoints:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Narrower endpoints:
None
Summary Statistics
↥Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | 236 | 199 | 37 |
Unadjusted prevalence (%) | 0.06 | 0.09 | 0.02 |
Mean age at first event (years) | 39.60 | 39.37 | 40.83 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: MSMED_FINGOLIMOD – Use of fingolimod
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Use of fingolimod
↥Endpoint not on priority list, no data to show.